355 related articles for article (PubMed ID: 20444895)
1. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
[TBL] [Abstract][Full Text] [Related]
2. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.
Lopez LA; Yang SJ; Exline CM; Rengarajan S; Haworth KG; Cannon PM
J Virol; 2012 May; 86(10):5467-80. PubMed ID: 22398279
[TBL] [Abstract][Full Text] [Related]
3. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
Lucas TM; Janaka SK; Stephens EB; Johnson MC
PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
[TBL] [Abstract][Full Text] [Related]
4. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.
Gupta RK; Mlcochova P; Pelchen-Matthews A; Petit SJ; Mattiuzzo G; Pillay D; Takeuchi Y; Marsh M; Towers GJ
Proc Natl Acad Sci U S A; 2009 Dec; 106(49):20889-94. PubMed ID: 19864625
[TBL] [Abstract][Full Text] [Related]
5. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
[TBL] [Abstract][Full Text] [Related]
7. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
8. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
9. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin.
Kühl A; Banning C; Marzi A; Votteler J; Steffen I; Bertram S; Glowacka I; Konrad A; Stürzl M; Guo JT; Schubert U; Feldmann H; Behrens G; Schindler M; Pöhlmann S
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S850-60. PubMed ID: 21987761
[TBL] [Abstract][Full Text] [Related]
10. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
11. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
12. CAML does not modulate tetherin-mediated restriction of HIV-1 particle release.
Ali MS; Hammonds J; Ding L; Spearman P
PLoS One; 2010 Feb; 5(2):e9005. PubMed ID: 20126395
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
15. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
Gupta RK; Hué S; Schaller T; Verschoor E; Pillay D; Towers GJ
PLoS Pathog; 2009 May; 5(5):e1000443. PubMed ID: 19461879
[TBL] [Abstract][Full Text] [Related]
16. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.
Lim ES; Malik HS; Emerman M
J Virol; 2010 Jul; 84(14):7124-34. PubMed ID: 20444900
[TBL] [Abstract][Full Text] [Related]
17. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
[TBL] [Abstract][Full Text] [Related]
20. Vpu binds directly to tetherin and displaces it from nascent virions.
McNatt MW; Zang T; Bieniasz PD
PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
